Добро пожаловать
Нажатие «Авторизоваться» означает, что вы соглашаетесь с Условия использования и политика конфиденциальности Cointime.
Зарегистрировать аккаунт
Аккаунт уже существует?
Нажатие «page.Sign up» означает, что вы соглашаетесь с <a class="underline" href="#term-of-service">Условия использования</a> и a class="underline" href="#privacy-policy">политика конфиденциальности</a> Cointime.
Войдите, используя email
Зарегистрируйтесь с помощью email
твой почтовый ящик
Проверь свои входящие
Нажмите на ссылку в , чтобы войти.
Нажмите на ссылку в , чтобы зарегистрироваться.
Madrigal Pharmaceuticals
company
About
Madrigal Pharmaceuticals develops therapeutics to improve the lives of patients with metabolic and fatty liver diseases.
- Conshohocken,Pennsylvania,United States
- 51 - 100
- http://madrigalpharma.com
Details
- Last Funding Type
- Post-IPO Equity
- Last Funding Money Raised
- $259M
- Industries
- Biotechnology,Medical Device,Pharmaceutical
- Founded date
- Jan 1, 2016
- Number Of Employee
- 51 - 100
- Operating Status
- Active
- Stock Symbol
- nasdaq:MDGL
- Legal Name
- Madrigal Pharmaceuticals, Inc.
- Also Known As
- VIA Pharmaceuticals
Madrigal Pharmaceuticals is developing novel, high-quality small-molecule drugs addressing major unmet needs in cardiovascular and metabolic diseases. The company is targeting treatment of both niche and prevalent indications, including diabetes, dyslipidemia and cardiovascular disease.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
6
$397.37M
Madrigal Pharmaceuticals has raised a total of
$397.37M
in funding over 2 rounds. Their latest funding was raised on
Dec 21, 2022 from a Post-IPO Equity round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Dec 21, 2022 | Post-IPO Equity | $259M | — | — | — | Detail |
| May 9, 2022 | Post-IPO Debt | $100M | 1 |
Hercules Capital
|
— | Detail |
| Jul 5, 2017 | Post-IPO Equity | $35M | — | — | — | Detail |
| May 2, 2016 | Post-IPO Debt | $3.37M | — | — | — | Detail |
| Apr 1, 2014 | Post-IPO Equity | — | 1 | — | — | Detail |
Investments
Number of Investments
Number of Lead Investments
5
0
Madrigal Pharmaceuticals has made 5 investments. Their most recent investment was on
Dec 12, 2022, when Evertas raised $14M.
|
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
|---|---|---|---|---|
|
Dec 12, 2022
Evertas
|
Series A | $14M | Blockchain | — |
|
Feb 24, 2022
Aligned
|
Seed | $34M | Blockchain | — |
|
Apr 12, 2021
The Defiant
|
Pre-seed | $1.40M | Finance | — |
|
Sep 11, 2020
BarnBridge
|
Seed | $1M | Bitcoin | — |
|
Jan 31, 2020
Molecule
|
Pre-seed | — | Blockchain | — |
Investors
Number of Lead Investors
Number of Investors
1
2
Madrigal Pharmaceuticals is funded by 2 investors.
Hercules Capital
and Bay City Capital
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Hercules Capital
|
Yes | Post-IPO Debt |
Bay City Capital
|
— | Post-IPO Equity |
Employee Profiles
Number of Employee Profiles
4
Madrigal Pharmaceuticals has 4 current employee profiles, including
Executive Rebecca Taub
Executive
Executive
Board member
Executive
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
